Boehringer Ingelheim

News

Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

News

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

Sales & Marketing

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

News

Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.

News

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.

News

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.